Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9959168 | 0.97 | NR1H4 (0.94) | NR1H4CYP3A4 | |
| SCHEMBL9958527 | 0.91 | NR1H4 (0.83) | NR1H4 | |
| SCHEMBL9952827 | 0.90 | NR1H4 (1.00) | NR1H4 | |
| SCHEMBL19122003 | 0.89 | NR1H4 (0.80) | NR1H4CYP3A4 | |
| SCHEMBL15294102 | 0.89 | NR1H4 (0.80) | NR1H4 | |
| SCHEMBL15294132 | 0.89 | NR1H4 (0.80) | NR1H4 | |
| SCHEMBL9959255 | 0.89 | NR1H4 (0.86) | NR1H4 | |
| SCHEMBL10085056 | 0.89 | NR1H4 (0.79) | NR1H4 | |
| SCHEMBL17128561 | 0.89 | NR1H4 (0.82) | NR1H4 | |
| SCHEMBL17128562 | 0.89 | NR1H4 (0.82) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655368-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-30 | — | — | EP | claimed |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-03 | — | — | US | claimed |
| WO-2012087520-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | claimed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| EP-2655368-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-03 | — | — | US | disclosed |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-03 | — | — | US | disclosed |
| WO-2012087520-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087520-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | NR1H4 11/4885CYP3A4 1746/4885 |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885CYP3A4 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.